$CYRX
Cryoport, Inc. Stock $cyrx

$cyrx Overview Financials Valuation SEC Filings Company Website

2018 Q1 Form 10-K Financial Statement

#000114420418013595 Filed on March 08, 2018

Income Statement

Concept	2018 Q1	2016 Q4	2016 Q3
Revenue	$4.023M	$2.229M	$1.977M
YoY Change	48.35%	52.78%	37.58%
Cost Of Revenue	$1.839M	$1.290M	$1.180M
YoY Change	26.06%	20.56%	17.92%
Gross Profit	$2.184M	$941.0K	$797.0K
YoY Change	74.33%	145.05%	82.8%
Gross Profit Margin	54.29%	42.22%	40.31%
Selling, General & Admin	$3.653M	$2.840M	$2.743M
YoY Change	31.73%	0.16%	26.99%
% of Gross Profit	167.23%	301.81%	344.16%
Research & Development	$329.7K	$100.0K	$214.7K
YoY Change	31.97%	-56.1%	114.05%
% of Gross Profit	15.1%	10.63%	26.94%
Depreciation & Amortization	$187.8K	$100.0K	$100.0K
YoY Change	42.78%	25.0%	150.0%
% of Gross Profit	8.6%	10.63%	12.55%
Operating Expenses	$3.983M	$2.940M	$2.958M
YoY Change	31.75%	-4.02%	30.98%
Operating Profit	-$1.798M	-$2.002M	-$2.161M
YoY Change	1.66%	-25.27%	18.62%
Interest Expense	$0.00	-$20.00K	$19.31K
YoY Change	-100.0%	-125.02%	-96.79%
% of Operating Profit
Other Income/Expense, Net	$15.77K	-$2.260M	$0.00
YoY Change		167680.25%	-100.0%
Pretax Income	-$2.682M	-$4.280M	-$2.182M
YoY Change	50.25%	55.06%	-10.05%
Income Tax	$813.00	$0.00	$2.878K
% Of Pretax Income
Net Earnings	-$2.683M	-$4.284M	-$2.184M
YoY Change	49.96%	55.19%	-9.96%
Net Earnings / Revenue	-66.68%	-192.19%	-110.47%
Basic Earnings Per Share
Diluted Earnings Per Share	-$100.1K	-$254.0K	-$144.2K
COMMON SHARES
Basic Shares Outstanding	27.34M shares	17.60M shares	15.12M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q1	2016 Q4	2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$19.00M	$4.500M	$2.600M
YoY Change	31.03%	-13.46%	-63.38%
Cash & Equivalents	$18.99M	$4.525M	$2.558M
Short-Term Investments
Other Short-Term Assets	$500.0K	$300.0K	$600.0K
YoY Change	66.67%	3.82%	200.0%
Inventory	$121.9K	$89.50K	$82.19K
Prepaid Expenses
Receivables	$2.400M	$1.195M	$1.000M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$22.04M	$6.096M	$4.247M
YoY Change	34.47%	-1.77%	-46.91%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.572M	$1.647M	$1.373M
YoY Change	22.49%	88.1%	71.65%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$400.0K	$400.0K	$400.0K
YoY Change	0.0%	0.0%
Total Long-Term Assets	$3.042M	$2.016M	$1.753M
YoY Change	21.33%	60.91%	94.75%
TOTAL ASSETS
Total Short-Term Assets	$22.04M	$6.096M	$4.247M
Total Long-Term Assets	$3.042M	$2.016M	$1.753M
Total Assets	$25.08M	$8.112M	$6.000M
YoY Change	32.72%	8.76%	-32.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.300M	$1.200M	$1.200M
YoY Change	-23.53%	9.09%	33.33%
Accrued Expenses	$1.100M	$400.0K	$400.0K
YoY Change	175.0%	0.0%	0.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$700.0K	$700.0K
YoY Change		-30.0%	-30.0%
Total Short-Term Liabilities	$2.400M	$2.231M	$2.292M
YoY Change	-8.89%	-9.6%	4.19%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$200.0K	$200.0K
YoY Change	0.0%
Total Long-Term Liabilities	$200.0K	$200.0K	$0.00
YoY Change	0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.400M	$2.231M	$2.292M
Total Long-Term Liabilities	$200.0K	$200.0K	$0.00
Total Liabilities	$2.632M	$2.432M	$2.292M
YoY Change	-7.12%	-1.49%	4.19%
SHAREHOLDERS EQUITY
Retained Earnings	-$134.1M	-$123.5M	-$119.3M
YoY Change
Common Stock	$156.6M	$129.2M	$122.9M
YoY Change	10.75%	13.01%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$22.45M	$5.680M	$3.698M
YoY Change
Total Liabilities & Shareholders Equity	$25.08M	$8.112M	$6.000M
YoY Change	32.72%	8.76%	-32.58%

Cashflow Statement

Concept	2018 Q1	2016 Q4	2016 Q3
OPERATING ACTIVITIES
Net Income	-$2.683M	-$4.284M	-$2.184M
YoY Change	49.96%	55.19%	-9.96%
Depreciation, Depletion And Amortization	$187.8K	$100.0K	$100.0K
YoY Change	42.78%	25.0%	150.0%
Cash From Operating Activities	-$1.064M	-$760.0K	-$1.530M
YoY Change	28.16%	-45.71%	42.99%
INVESTING ACTIVITIES
Capital Expenditures	$269.5K	-$390.0K	-$80.00K
YoY Change	-57.29%	5.41%	-65.22%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$284.9K	-$390.0K	-$80.00K
YoY Change	-55.57%	5.41%	-65.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00	$3.700M
YoY Change	-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	5.300M	3.120M	-360.0K
YoY Change	-53.83%	-7900.0%	-106.03%
NET CHANGE
Cash From Operating Activities	-1.064M	-760.0K	-1.530M
Cash From Investing Activities	-284.9K	-390.0K	-80.00K
Cash From Financing Activities	5.300M	3.120M	-360.0K
Net Change In Cash	3.952M	1.970M	-1.970M
YoY Change	-60.51%	-208.84%	-142.18%
FREE CASH FLOW
Cash From Operating Activities	-$1.064M	-$760.0K	-$1.530M
Capital Expenditures	$269.5K	-$390.0K	-$80.00K
Free Cash Flow	-$1.333M	-$370.0K	-$1.450M
YoY Change	-8.75%	-64.08%	72.62%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1647104	USD
CY2017Q2	dei	Entity Public Float EntityPublicFloat	116610411	USD
CY2017	dei	Trading Symbol TradingSymbol	CYRX
CY2018Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	27339977	shares
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4524529	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	6096426	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	5000	USD
CY2016Q4	us-gaap	Deposits Assets DepositsAssets	363403	USD
CY2016Q4	us-gaap	Assets Assets	8111933	USD
CY2016Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1160299	USD
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	419034	USD
CY2016Q4	us-gaap	Liabilities Liabilities	2431531	USD
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	17604	USD
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	129196680	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-123533882	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	5680402	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8111933	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1625476	USD
CY2017Q4	us-gaap	Inventory Net InventoryNet	114796	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	90646	USD
CY2017Q4	us-gaap	Deposits Assets DepositsAssets	363403	USD
CY2017Q4	us-gaap	Assets Assets	20264111	USD
CY2017Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1259629	USD
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	925514	USD
CY2017Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	0	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2185143	USD
CY2017Q4	us-gaap	Liabilities Liabilities	2377345	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-131432883	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	17886766	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	20264111	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	516427	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	286919	USD
CY2017Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	192202	USD
CY2016Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	200264	USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7899001	USD
CY2017	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.34
CY2017	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	22963382	shares
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	0	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10403036	USD
CY2017	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	0	USD
CY2017	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7420837	USD
CY2016	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6449196	USD
CY2017	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	5232406	USD
CY2016	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	4820230	USD
CY2017	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2016	us-gaap	Operating Expenses OperatingExpenses	11867532	USD
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	-8766109	USD
CY2016	us-gaap	Interest Expense InterestExpense	139416	USD
CY2016	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-6770	USD
CY2016	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	4195252	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	6123271	USD
	us-gaap	Cost Of Revenue CostOfRevenue	3603655	USD
	us-gaap	Gross Profit GrossProfit	2519616	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-6141991	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-13107547	USD
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5673	USD
	us-gaap	Interest Expense InterestExpense	58222	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1898	USD
	us-gaap	Net Income Loss NetIncomeLoss	-10403036	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.68
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	15393402	shares
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4634775	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3573204	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	4195252	USD
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1205692	USD
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	598106	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	453628	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2281233	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	47771	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3477781	USD
	cyrx	Adjustments To Additional Paid In Capital Warrants Repricing Expenses AdjustmentsToAdditionalPaidInCapitalWarrantsRepricingExpenses	3579352	USD
CY2017	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	70000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	989898	USD
CY2016Q1	us-gaap	Stockholders Equity StockholdersEquity	3095927	USD
	cyrx	Stock Issued During Period Value On April Tender Offer StockIssuedDuringPeriodValueOnAprilTenderOffer	2244247	USD
	cyrx	Stock Issued During Period Value On October Tender Offer StockIssuedDuringPeriodValueOnOctoberTenderOffer	3229111	USD
	cyrx	Adjustments To Additional Paid In Capital October Tender Offer Expenses AdjustmentsToAdditionalPaidInCapitalOctoberTenderOfferExpenses	615899	USD
CY2017	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	664831	USD
CY2016	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	84784	USD
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	3547781	USD
CY2016	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	374202	USD
CY2017	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	6130	USD
CY2017	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	11646	USD
CY2016	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	2503	USD
CY2017	us-gaap	Increase Decrease In Long Term Receivables Current IncreaseDecreaseInLongTermReceivablesCurrent	441643	USD
CY2016	us-gaap	Increase Decrease In Long Term Receivables Current IncreaseDecreaseInLongTermReceivablesCurrent	581197	USD
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	3117946	USD
CY2017	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	-186030	USD
CY2016	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	-169053	USD
CY2017	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	25297	USD
CY2016	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	74895	USD
CY2017	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	123249	USD
CY2016	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	51320	USD
CY2017	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	506480	USD
CY2016	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	41921	USD
CY2017	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-1843	USD
CY2016	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	11409	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3583126	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5718876	USD
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1714931	USD
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1062926	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1800577	USD
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1067926	USD
CY2017	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
CY2016	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
CY2017	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	656221	USD
CY2016	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	399350	USD
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	15901363	USD
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6063906	USD
CY2017	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	10517660	USD
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-722896	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5247425	USD
CY2017	cyrx	Proceeds From Rights Offering Net Of Offering Cost ProceedsFromRightsOfferingNetOfOfferingCost	0	USD
CY2016	cyrx	Proceeds From Rights Offering Net Of Offering Cost ProceedsFromRightsOfferingNetOfOfferingCost	-989898	USD
CY2017	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	5151660	USD
CY2016	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2017	cyrx	Noncash Or Part Noncash Acquisition Reclassification Of Shipper Inventory To Fixed Assets NoncashOrPartNoncashAcquisitionReclassificationOfShipperInventoryToFixedAssets	0	USD
CY2016	cyrx	Noncash Or Part Noncash Acquisition Reclassification Of Shipper Inventory To Fixed Assets NoncashOrPartNoncashAcquisitionReclassificationOfShipperInventoryToFixedAssets	38276	USD
CY2017	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	85646	USD
CY2016	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	5000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	301297	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	18729	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2329003	USD
	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	-37588	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	42646	USD
	us-gaap	Increase Decrease In Long Term Receivables Current IncreaseDecreaseInLongTermReceivablesCurrent	217126	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	19698	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	88637	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-89720	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	11410	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3743208	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	657667	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-662667	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	325378	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6137878	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1732003	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2792526	USD
	cyrx	Proceeds From Rights Offering Net Of Offering Cost ProceedsFromRightsOfferingNetOfOfferingCost	-989898	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
	cyrx	Noncash Or Part Noncash Acquisition Reclassification Of Shipper Inventory To Fixed Assets NoncashOrPartNoncashAcquisitionReclassificationOfShipperInventoryToFixedAssets	0	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	5000	USD
CY2017	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	261489	USD
CY2016	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2046	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	38190	USD
CY2017	us-gaap	Interest Paid Net InterestPaidNet	4744	USD
CY2016	us-gaap	Interest Paid Net InterestPaidNet	9534	USD
	us-gaap	Interest Paid Net InterestPaidNet	43223	USD
CY2017	us-gaap	Income Taxes Paid IncomeTaxesPaid	5143	USD
CY2016	us-gaap	Income Taxes Paid IncomeTaxesPaid	5673	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	5673	USD
CY2017	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
CY2016	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	1068055	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
CY2017	cyrx	Debt Conversion Converted Instrument Related Party Amount Warrant Issued DebtConversionConvertedInstrumentRelatedPartyAmountWarrantIssued	0	USD
CY2016	cyrx	Debt Conversion Converted Instrument Related Party Amount Warrant Issued DebtConversionConvertedInstrumentRelatedPartyAmountWarrantIssued	26901	USD
	cyrx	Debt Conversion Converted Instrument Related Party Amount Warrant Issued DebtConversionConvertedInstrumentRelatedPartyAmountWarrantIssued	0	USD
CY2017	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	0	USD
CY2016	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	200000	USD
	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	0	USD
CY2017	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	11405924	USD
CY2016	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2017	cyrx	Maturity Period Of Highly Liquid Investments MaturityPeriodOfHighlyLiquidInvestments	P90D
CY2017Q4	us-gaap	Cash Cash	14800000	USD
CY2017Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	USD
CY2016Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	75000	USD
CY2017Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	70000	USD
CY2017	us-gaap	Other Preferred Stock Dividends And Adjustments OtherPreferredStockDividendsAndAdjustments	0	USD
	us-gaap	Other Preferred Stock Dividends And Adjustments OtherPreferredStockDividendsAndAdjustments	0	USD
CY2017Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	104745	USD
CY2016Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	58655	USD
CY2017Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	10051	USD
CY2016Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	30844	USD
CY2017Q4	cyrx	Cryogenic Shippers And Data Loggers CryogenicShippersAndDataLoggers	2107642	USD
CY2016Q4	cyrx	Cryogenic Shippers And Data Loggers CryogenicShippersAndDataLoggers	1525409	USD
CY2017Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	63411	USD
CY2016Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	59961	USD
CY2017Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	519198	USD
CY2016Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	474681	USD
CY2017Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	362476	USD
CY2016Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	310398	USD
CY2017Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	436620	USD
CY2016Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	426105	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1546861	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1256048	USD
CY2016Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	106598	USD
CY2017Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	568688	USD
CY2017	us-gaap	Depreciation Depreciation	664800	USD
	us-gaap	Depreciation Depreciation	292700	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	597820	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	592820	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	683466	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	592820	USD
CY2016Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3700000	USD
CY2016Q2	cyrx	Class Of Warrant Or Right Number Of Warrants Exercised ClassOfWarrantOrRightNumberOfWarrantsExercised	2020597	shares
CY2016Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	cyrx	Accrued Board Of Director Fees Current AccruedBoardOfDirectorFeesCurrent	0	USD
CY2016Q4	cyrx	Accrued Board Of Director Fees Current AccruedBoardOfDirectorFeesCurrent	46000	USD
CY2016Q4	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	646700	USD
CY2016Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	3.57
CY2017	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	USD
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	4.50
CY2016Q4	cyrx	Class Of Warrant Or Rights Expiration Date ClassOfWarrantOrRightsExpirationDate	2019-10-28
CY2016Q4	cyrx	Class Of Warrant Or Right Number Of Warrants Exercised ClassOfWarrantOrRightNumberOfWarrantsExercised	2470913	shares
CY2016Q4	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	2470913	shares
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	8600	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	0	USD
CY2017Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	617984	USD
CY2016Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	166008	USD
CY2017Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	307530	USD
CY2016Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	207026	USD
CY2017Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.88
CY2017	us-gaap	Legal Fees LegalFees	5000	USD
CY2017	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	9600	USD
	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	39500	USD
CY2017Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	0	USD
CY2016Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	11400	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	405609	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	416370	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	428868	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	441736	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	454984	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	274405	USD
CY2017	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	298500	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	222700	USD
CY2017	cyrx	Consulting Service Fee ConsultingServiceFee	179100	USD
	cyrx	Consulting Service Fee ConsultingServiceFee	252600	USD
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2500000	shares
CY2016Q1	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	4977038	shares
CY2016Q1	cyrx	Class Of Warrant Or Right Number Of Warrants Exercised ClassOfWarrantOrRightNumberOfWarrantsExercised	4977038	shares
CY2017Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	10463970	shares
CY2017	cyrx	Warrants Exercised Intrinsic Value WarrantsExercisedIntrinsicValue	7100000	USD
	cyrx	Warrants Exercised Intrinsic Value WarrantsExercisedIntrinsicValue	3200000	USD
CY2017Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	797600	USD
CY2016Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	20668000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	15307000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	56000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	100000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2316000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2014000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	43000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	41000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	23083000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	17462000	USD
CY2016	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-3535000	USD
CY2016	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	607000	USD
CY2017	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-2684000	USD
CY2016	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-196000	USD
CY2017	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-277000	USD
CY2016	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	41000	USD
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.14
CY2016Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.25
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.1
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.08
CY2017	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	503000	USD
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.08
CY2017Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.09
CY2017	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	56000	USD
CY2016	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1663000	USD
CY2017	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-5625000	USD
CY2016	cyrx	Effective Income Tax Rate Reconciliation Nondeductible Expense Warrant Inducement And Repricing Costs Amount EffectiveIncomeTaxRateReconciliationNondeductibleExpenseWarrantInducementAndRepricingCostsAmount	1426000	USD
CY2017	cyrx	Effective Income Tax Rate Reconciliation Nondeductible Expense Warrant Inducement And Repricing Costs Amount EffectiveIncomeTaxRateReconciliationNondeductibleExpenseWarrantInducementAndRepricingCostsAmount	0	USD
CY2017Q1	us-gaap	Sales Revenue Net SalesRevenueNet	2712000	USD
CY2017Q2	us-gaap	Sales Revenue Net SalesRevenueNet	2917000	USD
CY2017Q3	us-gaap	Sales Revenue Net SalesRevenueNet	3003000	USD
CY2017Q4	us-gaap	Sales Revenue Net SalesRevenueNet	3322000	USD
CY2016Q1	us-gaap	Sales Revenue Net SalesRevenueNet	0	USD
CY2016Q2	us-gaap	Sales Revenue Net SalesRevenueNet	1918000	USD
CY2016Q3	us-gaap	Sales Revenue Net SalesRevenueNet	1977000	USD
CY2016Q4	us-gaap	Sales Revenue Net SalesRevenueNet	2229000	USD
CY2017Q1	us-gaap	Gross Profit GrossProfit	1253000	USD
CY2017Q2	us-gaap	Gross Profit GrossProfit	1393000	USD
CY2017Q3	us-gaap	Gross Profit GrossProfit	1606000	USD
CY2017Q4	us-gaap	Gross Profit GrossProfit	1713000	USD
CY2016Q1	us-gaap	Gross Profit GrossProfit	0	USD
CY2016Q2	us-gaap	Gross Profit GrossProfit	782000	USD
CY2016Q3	us-gaap	Gross Profit GrossProfit	797000	USD
CY2016Q4	us-gaap	Gross Profit GrossProfit	941000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1769000	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1864000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1988000	USD
CY2017Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-2271000	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	0	USD
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1979000	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2161000	USD
CY2016Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-2002000	USD
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0
CY2016Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.28
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	0	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-3935000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-2184000	USD
CY2016Q4	us-gaap	Net Income Loss NetIncomeLoss	-4284000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-1789000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-1860000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-1980000	USD
CY2017Q4	us-gaap	Net Income Loss NetIncomeLoss	-2270000	USD
CY2017	us-gaap	Nature Of Operations NatureOfOperations	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="center"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>Note 1. Nature of the Business</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Cryoport, Inc. (“Cryoport”) is the premier provider of cryogenic logistics solutions to the life sciences industry through its purpose-built proprietary packaging, information technology and specialized cold chain logistics expertise. The Company provides leading edge logistics solutions for biologic materials, such as immunotherapies, stem cells, CAR-T cells and reproductive cells for clients worldwide. Leading global companies, such as FedEx, UPS and DHL have each separately selected Cryoport as the preferred cryogenic logistics provider for time- and temperature-sensitive biological material.  Cryoport actively supports points-of-care, contract research organizations, central laboratories, pharmaceutical companies, contract manufacturers and university researchers.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company is a Nevada corporation and its <font style="BACKGROUND-COLOR: transparent">common stock is traded on the NASDAQ Capital Market exchange under the ticker symbol “CYRX.”</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><i>Use of Estimates</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from estimated amounts. The Company’s significant estimates include the allowance for doubtful accounts, recoverability of long-lived assets, allowance for inventory obsolescence, deferred taxes and their accompanying valuations, and valuation of equity instruments.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><i>Concentrations of Credit Risk</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company maintains its cash accounts in financial institutions. Accounts at these institutions are insured by the Federal Deposit Insurance Corporation (“FDIC”) with basic deposit insurance coverage limits up to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">250,000</font> per owner. At December 31, 2017, the Company had cash balances of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">14.8</font> million which exceeded the FDIC insurance limit. The Company performs ongoing evaluations of these institutions to limit its concentration risk exposure.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25701924	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25701924	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	17604283	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	17604283	shares
CY2017	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1356	USD
CY2016	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4341438	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4255372	USD
CY2017	cyrx	Stock Issued During Period Value New Issues Under Offering StockIssuedDuringPeriodValueNewIssuesUnderOffering	11405924	USD
CY2017	cyrx	Stock Issued During Period Value Stock Options And Warrants Exercised StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised	5151660	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	170326	USD
CY2017	cyrx	Deferred Offering Costs In Connection With Warrant Repricing DeferredOfferingCostsInConnectionWithWarrantRepricing	31981	USD
CY2016	cyrx	Deferred Offering Costs In Connection With Warrant Repricing DeferredOfferingCostsInConnectionWithWarrantRepricing	0	USD
	cyrx	Deferred Offering Costs In Connection With Warrant Repricing DeferredOfferingCostsInConnectionWithWarrantRepricing	0	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2500000	shares
CY2017	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9162082	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	165189	shares
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4058035	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2903152	USD
CY2016Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2017Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2017	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	8032000	USD
CY2016	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	USD
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35	pure
CY2017	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	8000000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	2421972	USD
CY2017	cyrx	Stock Issued During Period Shares Cashless Exercise Of Warrants StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants	144164	shares
CY2017Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	261083	shares

Files In Submission

Name	View Source	Status
0001144204-18-013595-index-headers.html	Edgar Link	pending
0001144204-18-013595-index.html	Edgar Link	pending
0001144204-18-013595.txt	Edgar Link	pending
0001144204-18-013595-xbrl.zip	Edgar Link	pending
cyrx-20171231.xml	Edgar Link	completed
cyrx-20171231.xsd	Edgar Link	pending
cyrx-20171231_cal.xml	Edgar Link	unprocessable
cyrx-20171231_def.xml	Edgar Link	unprocessable
cyrx-20171231_lab.xml	Edgar Link	unprocessable
cyrx-20171231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tv487333_10k.htm	Edgar Link	pending
tv487333_ex21.htm	Edgar Link	pending
tv487333_ex23-1.htm	Edgar Link	pending
tv487333_ex31-1.htm	Edgar Link	pending
tv487333_ex31-2.htm	Edgar Link	pending
tv487333_ex32-1.htm	Edgar Link	pending
tv487333_ex32-2.htm	Edgar Link	pending
tv487333_img1.jpg	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CYRX
Cryoport, Inc. Stock $cyrx

2018 Q1 Form 10-K Financial Statement

#000114420418013595 Filed on March 08, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CYRX Cryoport, Inc. Stock $cyrx

2018 Q1 Form 10-K Financial Statement

#000114420418013595 Filed on March 08, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CYRX
Cryoport, Inc. Stock $cyrx